首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1820630

全球減毒活疫苗市場研究報告 - 產業分析、規模、佔有率、成長、趨勢及預測（2025 年至 2033 年）

Global Live Attenuated Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年07月01日 | 出版商:

Value Market Research | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球減毒活疫苗市場預計將大幅成長，預計市場規模將從 2024 年的 212.3 億美元飆升至 2033 年的 529.1 億美元，預測期內年複合成長率(CAGR) 高達 10.68%。

全球減毒活疫苗市場預計將迎來強勁成長，這得益於免疫接種計畫的不斷增加以及對有效、持久的傳染病免疫力的需求。基因工程和病毒載體技術的進步正在推動更安全、更有針對性的減毒活疫苗的開發。未來的創新將專注於耐熱製劑和無針給藥系統，以提高疫苗的可及性和依從性。

此外，新冠疫情加速了疫苗研發和產能擴張。新興市場日益增強的疫苗意識和政府措施正在擴大疫苗接種覆蓋率。監管協調和公私合作正在促進疫苗的市場准入和分銷。隨著全球衛生重點的演變，減毒活疫苗市場將持續創新，提供安全、有效且易於取得的免疫解決方案。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業趨勢
波特五力分析
市場吸引力分析
- 按疫苗類型進行的市場吸引力分析
- 按發展分析市場吸引力
- 依管理模式分析市場吸引力
- 按年齡分析市場吸引力
- 按適應症分析市場吸引力
- 按最終用途進行的市場吸引力分析
- 市場吸引力分析：按地區

第4章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料製造商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第5章：全球減毒活疫苗市場分析：依疫苗類型

依疫苗類型概述
依疫苗類型分析歷史和預測數據
細菌疫苗
病毒疫苗

第6章：全球減毒活疫苗市場分析：按發展

按開發概述
按開發進行的歷史和預測數據分析
組織培養
胚胎卵
活體動物

第7章：全球減毒活疫苗市場分析：依給藥方式

依管理模式概述
按管理模式進行的歷史和預測資料分析
口服
注射劑
鼻內

第8章：全球減毒活疫苗市場分析：依年齡層

按年齡層別概覽
按年齡層別進行的歷史和預測資料分析
兒科
成人

第9章：全球減毒活疫苗市場分析：按適應症

按適應症概述
依適應症分析歷史和預測數據
結核
麻疹
輪狀病毒
黃熱病
口服小兒麻痺
流感
其他適應症

第 10 章：全球減毒活疫苗市場分析：依最終用途

按最終用途概述
按最終用途進行的歷史和預測數據分析
醫院（公立、私立）
專科診所
其他最終用戶

第 11 章：全球減毒活疫苗市場分析：按地區

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區分部銷售分析
- 亞太地區國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲分部銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第 12 章：減毒活疫苗公司的競爭格局

減毒活疫苗市場競爭
夥伴關係/合作/協議
併購
新產品發布
其他發展

第13章：公司簡介

頂級公司市佔率分析
市場集中度
Abbott

公司概況
公司收入
產品
最新動態

Bharat Biotech International Limited

公司概況
公司收入
產品
最新動態

Boehringer Ingelheim International GmbH

公司概況
公司收入
產品
最新動態

GlaxoSmithKline Plc

公司概況
公司收入
產品
最新動態

Haffkine Biopharmaceutical Corporation Limited

公司概況
公司收入
產品
最新動態

公司概況
公司收入
產品
最新動態

Merck & Co.

公司概況
公司收入
產品
最新動態

Novartis Pharmaceuticals Corporation

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

Serum Institute Of India Ltd.

公司概況
公司收入
產品
最新動態

Valneva SE

公司概況
公司收入
產品
最新動態

Zydus Group

公司概況
公司收入
產品
最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，或者在私人公司的情況下可能不涵蓋

簡介目錄圖表

Product Code: VMR112114275

Global Live Attenuated Vaccines Market is poised for a significant growth, with market size projected to surge from USD 21.23 Billion in 2024 to USD 52.91 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 10.68% during the forecast period.

The global live attenuated vaccines market is set for robust growth driven by increasing immunization programs and demand for effective, long-lasting immunity against infectious diseases. Advances in genetic engineering and viral vector technologies are enabling development of safer, more targeted live attenuated vaccines. Future innovations will focus on thermostable formulations and needle-free delivery systems to improve accessibility and compliance.

Moreover, the COVID-19 pandemic has accelerated vaccine research and manufacturing capacity expansion. Growing awareness and government initiatives in emerging markets are expanding vaccination coverage. Regulatory harmonization and public-private partnerships are facilitating market entry and distribution. As global health priorities evolve, the live attenuated vaccines market will continue to innovate, delivering safe, efficacious, and accessible immunization solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Live Attenuated Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

Bacterial Vaccine
Viral Vaccine

By Development

Tissue Culture
Embryonated Eggs
Live Animals

By Mode Of Administration

Oral
Injectable
Intranasal

By Age Group

Pediatric
Adult

By Indication

Tuberculosis
Measles
Rotavirus
Yellow Fever
Oral Polio
Influenza
Other Indications

By End-Use

Hospitals (Public, Private)
Specialty Clinics
Other End-Users
List of Companies Profiled in the report
Abbott, Bharat Biotech International Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Haffkine Biopharmaceutical Corporation Limited, HBI, Merck & Co., Novartis Pharmaceuticals Corporation, Sanofi, Serum Institute of India Ltd., Valneva SE, Zydus Group.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIVE ATTENUATED VACCINES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Vaccine Type
- 3.7.2 Market Attractiveness Analysis By Development
- 3.7.3 Market Attractiveness Analysis By Mode Of Administration
- 3.7.4 Market Attractiveness Analysis By Age Group
- 3.7.5 Market Attractiveness Analysis By Indication
- 3.7.6 Market Attractiveness Analysis By End-Use
- 3.7.7 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY VACCINE TYPE

5.1. Overview By Vaccine Type
5.2. Historical and Forecast Data Analysis By Vaccine Type
5.3. Bacterial Vaccine Historic and Forecast Sales By Regions
5.4. Viral Vaccine Historic and Forecast Sales By Regions

6. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY DEVELOPMENT

6.1. Overview By Development
6.2. Historical and Forecast Data Analysis By Development
6.3. Tissue Culture Historic and Forecast Sales By Regions
6.4. Embryonated Eggs Historic and Forecast Sales By Regions
6.5. Live Animals Historic and Forecast Sales By Regions

7. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY MODE OF ADMINISTRATION

7.1. Overview By Mode Of Administration
7.2. Historical and Forecast Data Analysis By Mode Of Administration
7.3. Oral Historic and Forecast Sales By Regions
7.4. Injectable Historic and Forecast Sales By Regions
7.5. Intranasal Historic and Forecast Sales By Regions

8. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY AGE GROUP

8.1. Overview By Age Group
8.2. Historical and Forecast Data Analysis By Age Group
8.3. Pediatric Historic and Forecast Sales By Regions
8.4. Adult Historic and Forecast Sales By Regions

9. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY INDICATION

9.1. Overview By Indication
9.2. Historical and Forecast Data Analysis By Indication
9.3. Tuberculosis Historic and Forecast Sales By Regions
9.4. Measles Historic and Forecast Sales By Regions
9.5. Rotavirus Historic and Forecast Sales By Regions
9.6. Yellow Fever Historic and Forecast Sales By Regions
9.7. Oral Polio Historic and Forecast Sales By Regions
9.8. Influenza Historic and Forecast Sales By Regions
9.9. Other Indications Historic and Forecast Sales By Regions

10. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY END-USE

10.1. Overview By End-Use
10.2. Historical and Forecast Data Analysis By End-Use
10.3. Hospitals (Public, Private) Historic and Forecast Sales By Regions
10.4. Specialty Clinics Historic and Forecast Sales By Regions
10.5. Other End-Users Historic and Forecast Sales By Regions

11. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY GEOGRAPHY

11.1. Regional Outlook
11.2. Introduction
11.3. North America Sales Analysis
- 11.3.1 Overview, Historic and Forecast Data Sales Analysis
- 11.3.2 North America By Segment Sales Analysis
- 11.3.3 North America By Country Sales Analysis
- 11.3.4 United States Sales Analysis
- 11.3.5 Canada Sales Analysis
- 11.3.6 Mexico Sales Analysis
11.4. Europe Sales Analysis
- 11.4.1 Overview, Historic and Forecast Data Sales Analysis
- 11.4.2 Europe By Segment Sales Analysis
- 11.4.3 Europe By Country Sales Analysis
- 11.4.4 United Kingdom Sales Analysis
- 11.4.5 France Sales Analysis
- 11.4.6 Germany Sales Analysis
- 11.4.7 Italy Sales Analysis
- 11.4.8 Russia Sales Analysis
- 11.4.9 Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
- 11.5.1 Overview, Historic and Forecast Data Sales Analysis
- 11.5.2 Asia Pacific By Segment Sales Analysis
- 11.5.3 Asia Pacific By Country Sales Analysis
- 11.5.4 China Sales Analysis
- 11.5.5 India Sales Analysis
- 11.5.6 Japan Sales Analysis
- 11.5.7 South Korea Sales Analysis
- 11.5.8 Australia Sales Analysis
- 11.5.9 South East Asia Sales Analysis
- 11.5.10 Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
- 11.6.1 Overview, Historic and Forecast Data Sales Analysis
- 11.6.2 Latin America By Segment Sales Analysis
- 11.6.3 Latin America By Country Sales Analysis
- 11.6.4 Brazil Sales Analysis
- 11.6.5 Argentina Sales Analysis
- 11.6.6 Peru Sales Analysis
- 11.6.7 Chile Sales Analysis
- 11.6.8 Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
- 11.7.1 Overview, Historic and Forecast Data Sales Analysis
- 11.7.2 Middle East & Africa By Segment Sales Analysis
- 11.7.3 Middle East & Africa By Country Sales Analysis
- 11.7.4 Saudi Arabia Sales Analysis
- 11.7.5 UAE Sales Analysis
- 11.7.6 Israel Sales Analysis
- 11.7.7 South Africa Sales Analysis
- 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE LIVE ATTENUATED VACCINES COMPANIES

12.1. Live Attenuated Vaccines Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments

13. COMPANY PROFILES OF LIVE ATTENUATED VACCINES INDUSTRY

13.1. Top Companies Market Share Analysis
13.2. Market Concentration Rate
13.3. Abbott
- 13.3.1 Company Overview
- 13.3.2 Company Revenue
- 13.3.3 Products
- 13.3.4 Recent Developments
13.4. Bharat Biotech International Limited
- 13.4.1 Company Overview
- 13.4.2 Company Revenue
- 13.4.3 Products
- 13.4.4 Recent Developments
13.5. Boehringer Ingelheim International GmbH
- 13.5.1 Company Overview
- 13.5.2 Company Revenue
- 13.5.3 Products
- 13.5.4 Recent Developments
13.6. GlaxoSmithKline Plc
- 13.6.1 Company Overview
- 13.6.2 Company Revenue
- 13.6.3 Products
- 13.6.4 Recent Developments
13.7. Haffkine Biopharmaceutical Corporation Limited
- 13.7.1 Company Overview
- 13.7.2 Company Revenue
- 13.7.3 Products
- 13.7.4 Recent Developments
13.8. HBI
- 13.8.1 Company Overview
- 13.8.2 Company Revenue
- 13.8.3 Products
- 13.8.4 Recent Developments
13.9. Merck & Co.
- 13.9.1 Company Overview
- 13.9.2 Company Revenue
- 13.9.3 Products
- 13.9.4 Recent Developments
13.10. Novartis Pharmaceuticals Corporation
- 13.10.1 Company Overview
- 13.10.2 Company Revenue
- 13.10.3 Products
- 13.10.4 Recent Developments
13.11. Sanofi
- 13.11.1 Company Overview
- 13.11.2 Company Revenue
- 13.11.3 Products
- 13.11.4 Recent Developments
13.12. Serum Institute Of India Ltd.
- 13.12.1 Company Overview
- 13.12.2 Company Revenue
- 13.12.3 Products
- 13.12.4 Recent Developments
13.13. Valneva SE
- 13.13.1 Company Overview
- 13.13.2 Company Revenue
- 13.13.3 Products
- 13.13.4 Recent Developments
13.14. Zydus Group
- 13.14.1 Company Overview
- 13.14.2 Company Revenue
- 13.14.3 Products
- 13.14.4 Recent Developments